Show simple item record

dc.contributor.authorAmory, John K.en_US
dc.contributor.authorPage, Stephanie T.en_US
dc.contributor.authorBremner, William J.en_US
dc.contributor.authorAnawalt, Bradley D.en_US
dc.contributor.authorHerbst, Karen L.en_US
dc.contributor.authorCoviello, Andrea D.en_US
dc.date.accessioned2008-10-17T20:40:52Z
dc.date.available2008-10-17T20:40:52Z
dc.date.issued2004-12en_US
dc.identifier.citationJ Clin Endocrinol Metab. 2004 Dec;89(12):5959-65en_US
dc.identifier.urihttp://hdl.handle.net/1773/4325
dc.description.abstractAcyline is a novel GnRH antagonist that reliably inhibits gonadotropins and testosterone (T) levels in men for 48 h after a single dose up to 75 microg/kg. In this study we examined gonadotropin and T levels in 28 healthy young men administered acyline as single doses of 150 or 300 microg/kg or serial injections of 75 microg/kg. A single 300 microg/kg dose of acyline suppressed gonadotropins and T to castrate levels for 15 d (baseline, 21.1 +/- 3.1; nadir, 1.95 +/- 0.4 nmol/liter; mean +/- sem; P < 0.05). Serum acyline levels peaked 90 min after the injection of 300 microg/kg acyline to a maximum concentration of 112.4 +/- 18 ng/ml (n = 7; t(1/2) = 4.9 d). Injections of 75 microg/kg acyline every 2 d for five doses suppressed gonadotropins for more than 20 d (nadir T, 1.06 +/- 0.17 nmol/liter; P < 0.05 compared with baseline). Adverse events were mild and included erythema and pruritus at the injection site. Acyline, therefore, is one of the most potent peptide GnRH antagonists studied to date with minimal adverse events. A twice monthly injection of acyline could be used as a potent suppressor of the GnRH axis to advance the development of a hormonal male contraceptive or for treatment of hormonally dependent disease.en_US
dc.language.isoen_USen_US
dc.publisherEndocrine Societyen_US
dc.subjectmale contraceptionen_US
dc.subject5-alpha reductase inhibitorsen_US
dc.subjectandrologyen_US
dc.subjectgonadotropinsen_US
dc.subjecttestosteroneen_US
dc.subject.meshInjections, Subcutaneousen_US
dc.subject.meshHumansen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPruritus, chemically induceden_US
dc.subject.meshMaleen_US
dc.subject.meshDrug Administration Scheduleen_US
dc.subject.meshTime Factorsen_US
dc.subject.meshReference Valuesen_US
dc.subject.meshResearch Support, U.S. Gov't, P.H.S.en_US
dc.subject.meshOligopeptides, administration & dosage, adverse effects, blood, pharmacokinetics, pharmacologyen_US
dc.subject.meshGonadorelin, antagonists & inhibitorsen_US
dc.subject.meshGonadotropins, antagonists & inhibitors, blooden_US
dc.subject.meshErythema, chemically induceden_US
dc.subject.meshTestosterone, antagonists & inhibitors, blooden_US
dc.subject.meshAdulten_US
dc.titleA single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotropins and testosterone for 2 weeks in healthy young menen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record